Incobotulinum Toxin-A Improves Post-Surgical and Post-Radiation Pain in Cancer Patients
Abstract
Cancer patients who undergo surgery or radiation can develop persistent focal pain at the site of radiation or surgery. Twelve patients who had surgery or radiation for local cancer and failed at least two analgesic medications for pain control were prospectively enrolled in a research protocol. Patients were injected up to 100 units of incobotulinum toxin A (IncoA) intramuscularly or subcutaneously depending on the type and location of pain (muscle cramp or neuropathic pain). Two patients passed away, one dropped out due to a skin reaction and another patient could not return for the follow up due to his poor general condition. All remaining 8 subjects (Age 31-70, 4 female) demonstrated significant improvement of Visual Analog Scale (VAS) (3 to 9 degrees, average 3.9 degrees) and reported significant satisfaction in Patients' Global Impression of Change scale (PGIC) (7 out of 8 reported the pain as much improved). Three of the 8 patients reported significant improvement of quality of life.
Associated Clinical Trials
References
Botulinum toxin B in the sensory afferent: transmitter release, spinal activation, and pain behavior
Citations
Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia
Drug management of cancer-related peripheral neuropathic pain: A systematic review of the literature
Clinical Trials Mentioned
Related Concepts
Related Feeds
Botulism (ASM)
Botulism is a rare but serious paralytic illness caused by a nerve toxin that is produced by the bacterium clostridium botulinum. Discover the latest research on botulism here.
Botulism
Botulism is a rare but serious paralytic illness caused by a nerve toxin that is produced by the bacterium clostridium botulinum. Discover the latest research on botulism here.